Prevention & lipids

Discontinuing Statins in Older Adults without Cardiovascular Disease

N Engl J MedPublished international, open-label, randomized, controlled trial

Authors' conclusion

Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuation of statin therapy was noninferior to continuation with respect to major cardiovascular events or death from any cause at 2 years. (Funded by the Swiss National Science Foundation; STREAM ClinicalTrials.gov number, NCT05178420.).

Study context

Population
Adults at least 70 years of age with at least two chronic conditions but no known cardiovascular disease, taking statins for primary prevention
Participants
1,880 adults
Comparison
Discontinue or continue statin therapy and other lipid-lowering therapies
  • Discontinuation groupn = 938
  • Continuation groupn = 942
Primary endpoint
Composite of:
  • Nonfatal myocardial infarction
  • Nonfatal ischemic stroke
  • Death from any cause (restricted mean event-free survival time)
Follow-up
2 years
Methodological detailsnoninferiority, 1:1 randomization
  • Noninferiority
  • 1:1 randomization

Primary result

As reported in the abstract

Composite of nonfatal myocardial infarction, nonfatal ischemic stroke, or death from any cause…

Difference in restricted mean event-free survival time

−2.0 weeks

95% CI −3.7 to −0.3

P < 0.001 for noninferiority

Events by treatment group

Discontinuation groupvs continuation group
difference in restricted mean event-free survival time −2.0 weeks (95% CI −3.7 to −0.3); P < 0.001 for noninferiority

Further findings

Baseline characteristics

Mean age
77.5 years
Women
46.9%

Safety

At least one serious adverse event

Original publication

Discontinuing Statins in Older Adults without Cardiovascular Disease. N Engl J Med. Published 7 November 2026. doi:10.1056/nejmoa2606634

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.